Genomics|Update|Non Communicable Diseases ► Cancer

Genomics|Update|Non Communicable Diseases

Volume 34  Number 21  May 28 - June 4, 2015

Cancer

Barriers prevent patient access to personalized therapies identified by molecular tumor profiling of gynecologic malignancies. 
Hillman RT et al. J Pers Med 5(2) 165-173

Broad applicability of nivolumab in melanoma regardless of BRAF mutation status 
Gangadhar TC et al. JAMA Oncol. May 21, 2015

Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome. 
Zhu Y et al. Urol. Oncol. 2015 May 22.

Committee opinion no. 634: hereditary cancer syndromes and risk assessment. 
Obstet Gynecol 2015 Jun 125(6) 1538-43

Gene-panel sequencing and the prediction of breast-cancer risk 
Easton DF, et al. New England Journal of Medicine 2015 May 27

Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma 
Larkin J, et al. JAMA Oncol. May 21, 2015

Family history and outcome of young patients with breast cancer in the UK (POSH study). 
Eccles BK et al. Br J Surg 2015 May 20.

Getting personal: Head and neck cancer management in the era of genomic medicine. 
Birkeland AC et al. Head Neck 2015 May 20.

Integrative clinical genomics of advanced prostate cancer. 
Robinson D et al. Cell 2015 May 21. 161(5) 1215-28

Lung cancer in the era of precision medicine. 
Politi K et al. Clin. Cancer Res. 2015 May 15. 21(10) 2213-20

OncoRep: an n-of-1 reporting tool to support genome-guided treatment for breast cancer patients using RNA-sequencing. 
Meißner T et al. BMC Med Genomics 2015 8(1) 24

Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. 
Koitsalu M et al. Acta Oncol 2015 May 20. 1-7

Socio-ethical issues in personalized medicine: A systematic review of English language health technology assessments of gene expression profiling tests for breast cancer prognosis.
Ali-Khan SE et al. Int J Technol Assess Health Care 2015 May 20. 1-15

Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. 
Shih Ya-CT et al. J. Clin. Oncol. 2015 May 18.

Whole-genome characterization of chemoresistant ovarian cancer 
Patch AM, et al. Nature 2015 May 28

Targeted agent and profiling utilization registry study, ASCO